Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ESMO
ESMO
ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC
Fierce Biotech
Mon, 09/12/22 - 10:43 am
ESMO
Daiichi Sankyo
DS-7300
small cell lung cancer
Relay kicks off public offering, seeking $300M on heels of robust ESMO data
Endpoints
Mon, 09/12/22 - 10:39 am
ESMO
Relay Therapeutics
funding
ESMO 2022 – Springworks aims to Defi expectations
EP Vantage
Mon, 09/12/22 - 10:31 am
ESMO
desmoid tumors
GSK
ESMO: Amgen's Lumakras confirmatory lung cancer data are here, fanning KRAS battle flames
Fierce Pharma
Sun, 09/11/22 - 11:07 pm
Amgen
lung cancer
ESMO
KRAS inhibitors
ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some
Fierce Biotech
Sun, 09/11/22 - 10:58 pm
ESMO
Pfizer
Ipsen
EZH2 inhibitors
Epizyme
ESMO: Relay spotlights expanded FGFR2 inhibitor data it hopes will pave accelerated approval
Fierce Biotech
Sun, 09/11/22 - 10:57 pm
ESMO
Relay Therapeutics
RLY-4008
cholangiocarcinoma
ESMO: GSK keeps the faith in anti-TIGIT plans; it's 'not always about being first'
Fierce Biotech
Fri, 09/9/22 - 12:08 pm
GSK
anti-TIGIT
ESMO
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Yahoo Finance
Fri, 09/9/22 - 11:03 am
ESMO
Adaptimmune
clinical trials
ADP-A2M4CD8
ovarian cancer
head and neck cancer
urothelial cancer
Esmo 2022 – Galleri’s real-world exhibition disappoints
EP Vantage
Fri, 09/9/22 - 10:39 am
ESMO
Grail
Illumina
diagnostics
multi-cancer test
Galleri
ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda
Fierce Pharma
Thu, 09/8/22 - 04:40 pm
Merck
Keytruda
Astellas
Seagen
Padcev
ESMO
urothelial cancer
SpringWorks, Eli Lilly and More Release Data Ahead of ESMO
BioSpace
Thu, 09/8/22 - 04:30 pm
SpringWorks Therapeutics
nirogacestat
desmoid tumors
Eli Lilly
ESMO
ESMO 2022 – the new liver cancer entrants line up
EP Vantage
Thu, 09/8/22 - 10:39 am
ESMO
liver cancer
Keytruda
tislelizumab
camrelizumab
Merck
BeiGene
Novartis
ESMO 2022 – Keytruda secures a renal cancer monopoly
EP Vantage
Thu, 09/8/22 - 12:03 am
Merck
Keytruda
renal cancer
Bristol Myers Squibb
Roche
ESMO
ESMO: Gilead's Trodelvy makes surprise comeback with above-par breast cancer survival showing
Fierce Pharma
Wed, 09/7/22 - 11:59 pm
Gilead Sciences
Trodelvy
ESMO
HR-positive HER-negative breast cancer
breast cancer
At ESMO, three studies show promise of antibody-drug conjugates in breast cancer
Pharmaforum
Mon, 05/30/22 - 10:23 am
ESMO
breast cancer
antibody-drug conjugate
AstraZeneca
Janssen Licenses "Flexible Antibody" Technology from F-star in New Collab
BioSpace
Thu, 10/21/21 - 09:24 am
F-star Therapeutics
Janssen
FS120
ESMO
clinical trials
ESMO 2021 movers – a handful of biotech winners emerge
EP Vantage
Fri, 09/24/21 - 11:48 am
ESMO
Corbus Pharmaceuticals
Leap Therapeutics
Surface Oncology
AstraZeneca
Innate Pharma
Immunocore
Daiichi Sankyo
Verastem
Spectrum Pharrmaceuticals
Mirati Therapeutics
ESMO 2021 – Astra coasts towards a new lung cancer combo
EP Vantage
Mon, 09/20/21 - 10:54 pm
ESMO
AstraZeneca
Imfinzi
oleclumab
Innate Pharma
non-small cell lung cancer
ESMO: Syros targets KRAS-mutant cancer as CDK7 inhibitor shows early promise
Fierce Biotech
Mon, 09/20/21 - 12:00 pm
ESMO
Syros Pharmaceuticals
breast cancer
Pfizer
Ibrance
Exelixis pulls a surprise win in thyroid cancer just days ahead of final Cabometyx readout
Endpoints
Mon, 09/20/21 - 11:57 am
ESMO
Exelixis
thyroid cancer
Cabometyx
Pages
« first
‹ previous
1
2
3
4
5
6
next ›
last »